Financial Tear Sheet

Corporate Profile

Quest Diagnostics is the world's leading provider of diagnostic testing, information and services that patients and doctors need to make better healthcare decisions. The company offers the broadest access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its extensive medical and scientific staff. Quest Diagnostics is a pioneer in developing innovative diagnostic tests and advanced healthcare information technology solutions that help improve patient care.

Primary IR Contact

Dan Haemmerle
Executive Director Investor Relations
Phone: 973-520-2900
Investor@QuestDiagnostics.com

Stock Performance

DGX (Common Stock)	
Exchange	NYSE (US Dollar)
Price	**$61.97**
Change (%)	▲ 0.85 (1.39%)
Volume	1,111,762
52 Week Low	$53.25
Market Cap	$9,793,057,130
Rolling EPS	3.67
PE Ratio	16.8856
Shares Outstanding	158,029,000
Data as of 05/23/13 4:02 p.m. ET	

Recent Press Releases

05/21/13
Quest Diagnostics Declares Quarterly Cash Dividend

05/16/13
Quest Diagnostics Acquires Concentra's Laboratory Business, Enters into Exclusive Services Agreement

05/13/13
Decades of Improving Cholesterol Levels Abruptly Ended in 2008, PLOS ONE Study Finds

Upcoming Events

There are currently no events scheduled.

Recent SEC Filings

Filing Date	Form	Description
05/17/13	4	Statement of changes in beneficial ownership of securities
05/15/13	4	Statement of changes in beneficial ownership of securities
05/03/13	4	Statement of changes in beneficial ownership of securities
05/03/13	4	Statement of changes in beneficial ownership of securities

Analyst Estimates / Ratings

Mean Recommendation: **3.0**



Sell *Strong Buy*

EPS Trend				
		Current	**30 Days Ago**	**90 Days Ago**
QTR	Jun 13	1.10	1.10	1.13
QTR	Sep 13	1.21	1.19	1.16
QTR	Dec 13	1.16	1.13	1.10
QTR	Mar 14	1.04	1.06	1.12
FY	Dec 13	4.35	4.37	4.41
FY	Dec 14	4.81	4.84	4.86

Board of Directors

Dan C. Stanzione, Ph.D.
Lead Independent Director and Non-Executive Chairman of the Board

John C. Baldwin, M.D.
Director

Jenne K. Britell, Ph.D.
Director

William F. Buehler
Director

Gary M. Pfeiffer
Director

Timothy M. Ring
Director

Stephen H. Rusckowski
President and Chief Executive Officer

Gail R. Wilensky, Ph.D.
Director

John B. Ziegler
Director

Management Team

Stephen H. Rusckowski
President and Chief Executive Officer

Jon R. Cohen, M.D.
Senior Vice President and Chief Medical Officer

Everett Cunningham
Senior Vice President, Commercial

James E. Davis
Senior Vice President, Diagnostic Solutions

Catherine T. Doherty
Senior Vice President, Clinical Franchises

Robert A. Hagemann
Senior Vice President and Chief Financial Officer

John B. Haydon
Senior Vice President, Operations

Michael E. Prevoznik
Senior Vice President and General Counsel

Jeffrey S. Shuman
Senior Vice President, Chief Human Resources Officer

Jay G. Wohlgemuth, M.D.
Senior Vice President, Science and Innovation

Gary D. Samuels
Vice President, Corporate Communications

Tim Sharpe
Vice President, Compliance

Dermot Shorten
Vice President, Strategy and Ventures

Ownership Summary

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
Capital World Investors	14,135,000	8.9	5,170,000	03/31/13
Aberdeen Asset Managers Ltd.	10,774,210	6.8	615,400	03/31/13
The Vanguard Group, Inc.	9,754,013	6.2	489,939	03/31/13
Fidelity Management & Research Company	8,449,281	5.4	5,275,248	03/31/13
T. Rowe Price Associates, Inc.	6,640,034	4.2	-3,353,186	03/31/13
State Street Global Advisors (US)	6,576,397	4.2	293,381	03/31/13
BlackRock Institutional Trust Company, N.A.	6,388,597	4.0	187,397	03/31/13
Harris Associates L.P.	5,126,400	3.2	-652,700	03/31/13
Delaware Investments	4,703,250	3.0	891,528	03/31/13
Relational Investors LLC	4,129,115	2.6	-1,042,316	03/31/13